Abivax Shares Surge 38.66% as Cancer Drug Safety Concern Reversed
ABVX•Abivax shares jumped 38.66% on July 1, erasing a month’s worth of declines in a single session. The rally followed investor relief over the resolution of a safety concern related to its lead oncology therapy candidate, restoring confidence in the company’s clinical pipeline.
1. Stock Performance Rebound
Abivax shares surged 38.66% in a single session on July 1, fully recouping losses from the prior month and delivering its steepest one-day advance to date.
2. Safety Review Clears Lead Candidate
The rebound followed the company’s clarification that its lead oncology therapy candidate showed no new safety issues in recent trials, alleviating investor concerns and restoring confidence in its clinical development trajectory.
